Clinical Trials Logo

Loss of Heterozygosity clinical trials

View clinical trials related to Loss of Heterozygosity.

Filter by:
  • None
  • Page 1

NCT ID: NCT04651933 Recruiting - Clinical trials for Epithelial Ovarian Cancer

A Training Set for the HRD Model in EOC

Start date: November 26, 2020
Phase:
Study type: Observational

A homologous recombination deficiency (HRD) scoring model based on loss of heterozygosity (LOH) is little explored in epithelial ovarian cancer (EOC) patients. This study would recruit 200 Chinese EOC patients with known BRCA1/2 mutation status and resistance to platinum-based chemotherapy. A LOH-HRD model is to be constructed based on the genetic testing in these patients. The mutated genes, HRD score model and their relationship with the prognosis, would provide a full description of for the Chinese EOC patients, and a potential explanation of platinum-resistance in such population.

NCT ID: NCT03845296 Active, not recruiting - Clinical trials for Stage IV Lung Cancer AJCC v8

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Start date: April 16, 2019
Phase: Phase 2
Study type: Interventional

This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back. Rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.